I have to disagree Scott. The previous updated sta
Post# of 9144
(Total Views: 640)
Posted On: 06/11/2021 8:13:43 AM
Re: mitstevfel #8320
I have to disagree Scott. The previous updated stated:
"NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system. Partial funding for the first phase of the feasibility assessment is being provided through NanoLogix Director and Chief Medical Officer Dr. Jonathan Faro and Director Dr. Sebastian Faro exercise of options for 3 million shares. Those exercised shares are restricted from trading for a period of one year from issuance."
If the diagnostic company found it to be feasible and that a platform was sent to a university for testing I would have expected that to be in the update. That's significant news for shareholders and potential investors. Why keep something like that out of the update? That's just as significant news, if not more, than news from other updates.
"NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system. Partial funding for the first phase of the feasibility assessment is being provided through NanoLogix Director and Chief Medical Officer Dr. Jonathan Faro and Director Dr. Sebastian Faro exercise of options for 3 million shares. Those exercised shares are restricted from trading for a period of one year from issuance."
If the diagnostic company found it to be feasible and that a platform was sent to a university for testing I would have expected that to be in the update. That's significant news for shareholders and potential investors. Why keep something like that out of the update? That's just as significant news, if not more, than news from other updates.
(5)
(0)